APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Conjugate Vaccine (PCV)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pneumococcal Conjugate Vaccine (PCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17402676032 January 2026182 pages

Choose your research edition.

Industry ResearchPneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Conjugate Vaccine (PCV) Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Pneumococcal Conjugate Vaccine (PCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Conjugate Vaccine (PCV) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Conjugate Vaccine (PCV) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pneumococcal Conjugate Vaccine (PCV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pneumococcal Conjugate Vaccine (PCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumococcal Conjugate Vaccine (PCV) include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Pneumococcal Conjugate Vaccine (PCV) market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Conjugate Vaccine (PCV) and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Conjugate Vaccine (PCV) revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Pneumococcal Conjugate Vaccine (PCV) market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Conjugate Vaccine (PCV) Segment by Company

Sanofi

Merck

Pfizer

GSK

Zhifei Biologic

Walvax Biotechnology

Serum Institute of India

Royal (Wuxi) Bio-Pharmaceutical

Pneumococcal Conjugate Vaccine (PCV) Segment by Type

10-valent Vaccine

13-valent Vaccine

23-valent Vaccine

7-valent Vaccine

Pneumococcal Conjugate Vaccine (PCV) Segment by Application

Child

Adult

Pneumococcal Conjugate Vaccine (PCV) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Pneumococcal Conjugate Vaccine (PCV) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Conjugate Vaccine (PCV) industry.

Chapter 3: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Conjugate Vaccine (PCV)revenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of 10-valent Vaccine Table 3. Key Players of 13-valent Vaccine Table 4. Key Players of 23-valent Vaccine Table 3. Key Players of 7-valent Vaccine Table 4. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Child Table 6. Key Players of Adult Table 7. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026) & (US$ Million) Table 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2021-2026) Table 10. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032) & (US$ Million) Table 11. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region (2027-2032) Table 12. Pneumococcal Conjugate Vaccine (PCV) Industry Trends Table 13. Pneumococcal Conjugate Vaccine (PCV) Industry Drivers Table 14. Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges Table 15. Pneumococcal Conjugate Vaccine (PCV) Industry Restraints Table 16. Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Company (US$ Million) & (2021-2026) Table 17. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Company (2021-2026) Table 18. Global Pneumococcal Conjugate Vaccine (PCV) Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global Pneumococcal Conjugate Vaccine (PCV) Key Company Head Office and Area Served Table 20. Global Pneumococcal Conjugate Vaccine (PCV) Company, Product Type & Application Table 21. Global Pneumococcal Conjugate Vaccine (PCV) Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global Pneumococcal Conjugate Vaccine (PCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 26. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 27. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2026) Table 28. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2027-2032) Table 29. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 31. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 32. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2026) Table 33. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2027-2032) Table 34. Sanofi Company Information Table 35. Sanofi Business Overview Table 36. Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 38. Sanofi Recent Development Table 39. Merck Company Information Table 40. Merck Business Overview Table 41. Merck Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 43. Merck Recent Development Table 44. Pfizer Company Information Table 45. Pfizer Business Overview Table 46. Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 48. Pfizer Recent Development Table 49. GSK Company Information Table 50. GSK Business Overview Table 51. GSK Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 53. GSK Recent Development Table 54. Zhifei Biologic Company Information Table 55. Zhifei Biologic Business Overview Table 56. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 58. Zhifei Biologic Recent Development Table 59. Walvax Biotechnology Company Information Table 60. Walvax Biotechnology Business Overview Table 61. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 63. Walvax Biotechnology Recent Development Table 64. Serum Institute of India Company Information Table 65. Serum Institute of India Business Overview Table 66. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 68. Serum Institute of India Recent Development Table 69. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 70. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 71. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio Table 73. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 74. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 75. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 76. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 77. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 78. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 79. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) Table 80. North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) Table 81. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 82. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 83. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 84. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 85. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) Table 87. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) Table 88. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 89. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 90. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 91. China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 93. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 94. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 95. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 96. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) Table 98. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) Table 99. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026) & (US$ Million) Table 100. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032) & (US$ Million) Table 101. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026) & (US$ Million) Table 102. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032) & (US$ Million) Table 103. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026) Table 105. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032) Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Pneumococcal Conjugate Vaccine (PCV) Product Image Figure 2. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Type: 2025 VS 2032 Figure 4. 10-valent Vaccine Image Figure 5. 13-valent Vaccine Image Figure 6. 23-valent Vaccine Image Figure 7. 7-valent Vaccine Image Figure 8. Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Application: 2025 VS 2032 Figure 10. Child Image Figure 11. Adult Image Figure 12. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 14. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Pneumococcal Conjugate Vaccine (PCV) Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Pneumococcal Conjugate Vaccine (PCV) Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Type (2021-2032) Figure 21. Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Application (2021-2032) Figure 23. North America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 24. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032) Figure 25. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032) Figure 26. North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 27. United States Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 28. Canada Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 30. Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 31. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032) Figure 32. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032) Figure 33. Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 34. Germany Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 35. France Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 37. Italy Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 38. Russia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 40. China Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 41. China Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032) Figure 42. China Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032) Figure 43. Asia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 44. Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032) Figure 45. Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032) Figure 46. Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 47. Japan Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 51. India Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 52. Australia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032) Figure 57. Brazil Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 62. UAE Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 64. Chile Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • 10-valent Vaccine
  • 13-valent Vaccine
  • 23-valent Vaccine
  • 7-valent Vaccine
Applications
  • Child
  • Adult
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • Zhifei Biologic
  • Walvax Biotechnology
  • Serum Institute of India
  • Royal (Wuxi) Bio-Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 10-valent Vaccine
  5. 1.2.3 13-valent Vaccine
  6. 1.2.4 23-valent Vaccine
  7. 1.2.5 7-valent Vaccine
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Child
  11. 1.3.3 Adult
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Pneumococcal Conjugate Vaccine (PCV) Growth Trends by Region
  14. 1.5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2021-2026)
  16. 1.5.3 Pneumococcal Conjugate Vaccine (PCV) Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Pneumococcal Conjugate Vaccine (PCV) Market Dynamics
  1. 2.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends
  2. 2.2 Pneumococcal Conjugate Vaccine (PCV) Industry Drivers
  3. 2.3 Pneumococcal Conjugate Vaccine (PCV) Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Conjugate Vaccine (PCV) Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Pneumococcal Conjugate Vaccine (PCV) Revenue by Company (2021-2026)
  2. 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Pneumococcal Conjugate Vaccine (PCV) Key Company Head office and Area Served
  4. 3.4 Global Pneumococcal Conjugate Vaccine (PCV) Company, Product Type & Application
  5. 3.5 Global Pneumococcal Conjugate Vaccine (PCV) Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Pneumococcal Conjugate Vaccine (PCV) Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Pneumococcal Conjugate Vaccine (PCV) Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Pneumococcal Conjugate Vaccine (PCV) Tier 1, Tier 2, and Tier 3
4 Pneumococcal Conjugate Vaccine (PCV) Market by Type
  1. 4.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2032)
  3. 4.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Type (2021-2032)
5 Pneumococcal Conjugate Vaccine (PCV) Market by Application
  1. 5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2032)
  3. 5.3 Global Pneumococcal Conjugate Vaccine (PCV) Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Merck
  8. 6.2.1 Merck Company Information
  9. 6.2.2 Merck Business Overview
  10. 6.2.3 Merck Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  12. 6.2.5 Merck Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 GSK
  20. 6.4.1 GSK Company Information
  21. 6.4.2 GSK Business Overview
  22. 6.4.3 GSK Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  24. 6.4.5 GSK Recent Developments
  25. 6.5 Zhifei Biologic
  26. 6.5.1 Zhifei Biologic Company Information
  27. 6.5.2 Zhifei Biologic Business Overview
  28. 6.5.3 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  30. 6.5.5 Zhifei Biologic Recent Developments
  31. 6.6 Walvax Biotechnology
  32. 6.6.1 Walvax Biotechnology Company Information
  33. 6.6.2 Walvax Biotechnology Business Overview
  34. 6.6.3 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  36. 6.6.5 Walvax Biotechnology Recent Developments
  37. 6.7 Serum Institute of India
  38. 6.7.1 Serum Institute of India Company Information
  39. 6.7.2 Serum Institute of India Business Overview
  40. 6.7.3 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  42. 6.7.5 Serum Institute of India Recent Developments
  43. 6.8 Royal (Wuxi) Bio-Pharmaceutical
  44. 6.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  45. 6.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  46. 6.8.3 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
  48. 6.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
7 North America
  1. 7.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  2. 7.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  3. 7.2.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026)
  4. 7.2.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032)
  5. 7.2.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032)
  6. 7.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  7. 7.3.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026)
  8. 7.3.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032)
  9. 7.3.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032)
  10. 7.4 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
  11. 7.4.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  13. 7.4.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
  14. 7.4.4 North America Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  2. 8.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  3. 8.2.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026)
  4. 8.2.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032)
  5. 8.2.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032)
  6. 8.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  7. 8.3.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026)
  8. 8.3.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032)
  9. 8.3.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032)
  10. 8.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
  11. 8.4.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  13. 8.4.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
  14. 8.4.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  2. 9.2 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  3. 9.2.1 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026)
  4. 9.2.2 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032)
  5. 9.2.3 China Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032)
  6. 9.3 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  7. 9.3.1 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026)
  8. 9.3.2 China Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032)
  9. 9.3.3 China Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  2. 10.2 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  3. 10.2.1 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026)
  4. 10.2.2 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032)
  5. 10.2.3 Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032)
  6. 10.3 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  7. 10.3.1 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026)
  8. 10.3.2 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032)
  9. 10.3.3 Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032)
  10. 10.4 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
  11. 10.4.1 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  13. 10.4.3 Asia Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
  14. 10.4.4 Asia Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst